Clinical trial · Observational
Observational Study for Lung Cancer Patients Treated With Nivolumab
EVIDENS: Lung Cancer Patients Treated With Nivolumab: A Longitudinal, Prospective, Observational, Multicentric Study
NCT03382496CI-TRIAL-00058708EVIDENScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will describe the characteristics of patients initiating nivolumab treatment for lung cancer and their outcomes over 3 years in France
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Lung Cancer patients in France
- description
- Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017
- interventionNames
- Other: Non-Interventional
Primary outcomes (18)
- measure
- Distribution of gender
- timeFrame
- At baseline
- measure
- Distribution of age
- timeFrame
- At baseline
- measure
- Distribution of line of therapy at nivolumab initiation
- timeFrame
- At baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female: 18 age at the time of nivolumab initiation * Pathologically confirmed diagnosis of lung cancer * Patient initiating nivolumab :therapeutic decision to initiate nivolumab must be taken by the physician prior to enrolling a patient in the study Exclusion Criteria: -Patient taking part in an interventional study for lung cancer treatment for which nivolumab is 1 of the investigational drugs Other protocol defined inclusion or exclusion criteria could apply
References
Publications (1)
- DERIVEDBarlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac JB, Benoit N, Bombaron P, Moro-Sibilot D, Audigier-Valette C, Asselain B, Egenod T, Rabeau A, Fayette J, Sanchez ML, Labourey JL, Westeel V, Lamoureux P, Cotte FE, Allan V, Daumont M, Dumanoir J, Reynaud D, Calvet CY, Ozan N, Perol M. Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. Oncoimmunology. 2020 Apr 12;9(1):1744898. doi: 10.1080/2162402X.2020.1744898. PMID 33457089